High-density lipoprotein metabolism: molecular targets for new therapies for atherosclerosis.
New therapeutic approaches to the prevention and treatment of atherosclerotic cardiovascular disease (ASCVD) are needed. Plasma levels of high-density lipoprotein (HDL) cholesterol are inversely associated with risk of ASCVD. Genes involved in the metabolism of HDL represent potential targets for the development of such therapies. Because HDL metabolism is a dynamic process, the effect of a specific HDL-oriented intervention on atherosclerosis cannot necessarily be predicted by its effect on the plasma HDL cholesterol level. Based on available data in animal models, some gene products are candidates for pharmacologic upregulation, infusion, or overexpression, including apolipoprotein (apo)A-I, apoE, apoA-IV, lipoprotein lipase (LPL), ATP-binding cassette protein 1 (ABC1), lecithin cholesterol acyltransferase (LCAT), and scavenger receptor B-I (SR-BI). In contrast, some gene products are potential candidates for inhibition, including apoA-II, cholesteryl ester transfer protein (CETP), and hepatic lipase. The next decade will witness the transition from preclinical studies to clinical trials of a variety of new therapies targeted toward HDL metabolism and atherosclerosis.
Kawashiri
M A
MA
University of Pennsylvania Medical Center, 614 BRBII/III, 421 Curie Blvd, Philadelphia, PA 19104, USA.
Maugeais
C
C
Rader
D J
DJ
D000818:Animals; D001161:Arteriosclerosis / Q000188:drug therapy* / Q000378:metabolism*; D015870:Gene Expression / Q000502:physiology; D006801:Humans; D008075:Lipoproteins, HDL / Q000235:genetics / Q000378:metabolism*
D008075:Lipoproteins, HDL